🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The June 25 edition of The Latino Newsletter is an opinion piece by Sonia Vega, a mother and wife from Phoenix, Arizona. Even with a full-time job and health insurance, she still can't afford her diabetes medication due to its high cost. thelatinonewsletter.org/p/latino-patie…

Staying current on the biggest news in drug pricing has never been easier with P4ADNOW's Week In Review! Published every Friday, WIR rounds up the latest news in drug pricing and delivers it straight to your inbox. Get in the know, subscribe now: mailchi.mp/654be71cbbf5/w…

Lawmakers from both parties are buying pharma stocks, major pharma-funded front groups continue efforts to protect drug industry profits, and P4AD Patient Advocate speaks up in op-ed about the need for affordable prescriptions in the U.S. Read more at our Week in Review:

Just days after patients helped keep the pharma-backed ORPHAN Cures Act out of the Senate reconciliation bill text, lawmakers have brought it back — but we still have a chance to stop it. “Patients are infuriated to see the Senate cave to Big Pharma by reviving the ORPHAN Cures

We have an urgent update. Some Senators are still working to get the pharma-backed ORPHAN Cures Act is back into the reconciliation bill after patients successfully kept it out. This harmful provision would be a $5 billion loophole to Big Pharma that weakens Medicare

The ORPHAN Cures Act is still on the table. It would exempt more from Medicare negotiation—costing taxpayers $5B and keeping prices high for patients. Send a letter to your senator urging them to OPPOSE the ORPHAN Cures Act: tinyurl.com/3dukzv9c

The Senate just passed a $5B pharma giveaway with no relief for patients with high drug prices. The ORPHAN Cures Act undermines Medicare negotiation and puts industry profits over people.

🆕 A recent poll from Fabrizio Ward and Arnold Ventures confirms what we know: the burden of high drug prices isn't a partisan issue. 1 in 3 Americans are affected by high drug costs and it's time for Congress to TAKE ACTION: PatientsPushForCompetition.org.

It’s official. Congress just passed a $5 billion taxpayer giveaway to Big Pharma — despite tens of thousands of patients demanding lower drug prices, not more backroom deals. Patients showed up, shared their stories, and made it clear: 9 out of 10 Americans want lower drug

Reconciliation bill includes $5 billion pharma giveaway, industry panics over possible “Most Favored Nation” pricing policy, and the FTC and DOJ held listening sessions on anti-competitive drug industry tactics. Read more at our Week in Review: tinyurl.com/3zkydn5s

Congress gave Big Pharma a win through the ORPHAN Cures Act by delaying lower Medicare drug prices for certain drugs and costing taxpayers $5 billion. This decision continues to put industry profits ahead of patients who rely on their medications. tinyurl.com/4ufe2bjx

Big Pharma says lower drug prices will hurt investment in new drugs – but the data proves that isn’t true. Since the passing of the 2022 prescription drug law, drug companies have increased research and development spending to $237B, proving its possible to have fairer prices and

We agree PBMs drive up costs. But that's not the whole story. Drug companies abuse the patent system to block generics & biosimilars- often filing 100+ patents on one drug- keeping prices high for patients. We need to fix both to truly lower drug prices. patientspushforcompetition.org

Five P4AD Patient Advocates joined HHS Secretary and NIH Director for a roundtable on high drug prices, a new report shows R&D spending soared to $247B after the IRA, & tariffs on pharmaceuticals are back in the spotlight. Read more at our Week in Review: tinyurl.com/yt3wf4tx

CMS launched an initiative to improve access and lower costs for sickle cell gene therapies, new "discounted" Eliquis may still be out of reach, FDA considering drug affordability in its new priority review voucher program. Read more at our Week in Review: tinyurl.com/5xa2bpdp

While drug companies rake in record profits, patients are struggling to pay for life saving prescription drugs. We know that drugs don't work if people can't afford them so why are we letting Big Pharma profit while patients suffer? Visit FightPharma.org to get involved.

👀 A Most Favored Nation policy (MFN), may just be the next big thing in drug pricing. Follow Patients For Affordable Drugs Now for the latest in MFN education and drug pricing news!

New reporting from Bloomberg Law's Nyah Phengsitthy on the Orphan Cures Act: "Drug pricing experts have gone as far to say the exemption walks back Trump’s agenda to lower US drug prices" — "it carves out more and more from negotiations" news.bloomberglaw.com/health-law-and…

Today, Senator Dick Durbin and Senator Chuck Grassley asked for unanimous consent in the Senate to pass their bipartisan DTC Act of 2025. Unfortunately, it was blocked. This bill would have given patients a drug’s price as it’s being marketed to them, helping patients make more

The FDA is expanding its priority review voucher program to include affordability as a key criterion, pharma’s claims that Medicare negotiation hurts innovation fall flat, AstraZeneca announced a $50B U.S. manufacturing investment, and industry-backed report warns that